How should I taper off low‑dose naltrexone (LDN) when taking 1.5 mg daily?

Tapering Low-Dose Naltrexone at 1.5 mg Daily

For patients taking low-dose naltrexone (LDN) at 1.5 mg daily, a gradual taper of 10% per month is recommended, reducing the dose by approximately 0.15 mg monthly until discontinuation, with close monitoring for withdrawal symptoms and underlying condition recurrence. 1

Understanding LDN Discontinuation Context

Low-dose naltrexone at 1.5 mg daily represents the starting dose in chronic pain protocols and is substantially lower than the standard 50 mg therapeutic dose used for opioid or alcohol dependence 2. Despite the low dose, discontinuation should still follow tapering principles because:

• Abrupt discontinuation of naltrexone has been associated with adverse events including mental health crises, requiring careful monitoring during any taper 1
• The 10% per month reduction strategy is well-tolerated for patients on long-term therapy (≥1 year), allowing gradual physiologic accommodation 3, 1

Recommended Tapering Protocol

Initial Assessment

• Before initiating the taper, screen for depression, anxiety, and insomnia, as these conditions should be addressed to improve taper outcomes 1
• Evaluate your motivation and readiness for discontinuation, as patient agreement is a key component of successful tapers 3
• Assess whether the underlying condition (fibromyalgia, neuropathic pain, or other chronic pain syndrome) is adequately controlled or if alternative treatments are in place 2

Specific Tapering Schedule for 1.5 mg Daily

• Month 1: Reduce to 1.35 mg daily (90% of 1.5 mg) 1, 4
• Month 2: Reduce to 1.2 mg daily (90% of 1.35 mg) 1
• Month 3: Reduce to 1.0 mg daily (approximately 90% of 1.2 mg) 1
• Month 4: Reduce to 0.75 mg daily 1
• Month 5: Reduce to 0.5 mg daily 1
• Month 6: Reduce to 0.25 mg daily 1
• Month 7: Extend dosing interval to every other day at 0.25 mg 3
• Month 8: Discontinue completely 3

Each new dose should be 90% of the previous dose rather than a straight-line reduction from the starting dose, as this hyperbolic taper is better tolerated 1, 4.

Monitoring and Support During Taper

Frequency of Follow-Up

• Schedule follow-up visits at least monthly during the tapering process 3
• Team members such as nurses, pharmacists, or behavioral health professionals can provide support through telephone contact, telehealth, or face-to-face visits 3

Withdrawal Symptoms to Monitor

• Watch for anxiety, insomnia, abdominal pain, vomiting, diarrhea, diaphoresis, mydriasis, tremor, tachycardia, or piloerection 3
• Monitor for dysphoria, irritability, anhedonia, or a vague sense of being unwell 4
• Clinically significant withdrawal symptoms signal the need to further slow the taper rate 3

Managing Withdrawal Symptoms

• α2-adrenergic agonists such as clonidine are well-supported for managing withdrawal symptoms 1
• Consider trazodone for insomnia, gabapentin for anxiety and irritability, and symptomatic treatments like NSAIDs or acetaminophen for muscle aches 1, 4
• For patients struggling to tolerate the taper, maximize non-pharmacologic treatments for pain and address behavioral distress 3

Special Considerations and Common Pitfalls

When to Pause or Slow the Taper

• If withdrawal symptoms emerge, the taper may need to be paused and restarted when you are ready 3
• Tapers may need to be slowed as you reach very low dosages (below 0.5 mg) 3
• Do not set zero as the mandatory target dose; some patients may benefit from maintenance at a lower dose if complete discontinuation proves difficult 1

Monitoring for Underlying Condition Recurrence

• Remain alert for return of chronic pain symptoms, as LDN was likely prescribed for fibromyalgia, neuropathic pain, or complex regional pain syndrome 2
• The average pain reduction with LDN is modest (approximately 0.83 points on pain scales), so discontinuation may result in gradual return of baseline pain levels 5
• Screen for anxiety, depression, and other comorbidities that may be revealed or worsened by the taper 3

Critical Pitfalls to Avoid

• Never abruptly discontinue naltrexone, even at low doses, as this can precipitate withdrawal symptoms and mental health crises 3, 1
• Do not fail to prepare for potential return of the underlying pain condition that prompted LDN initiation 2
• Avoid rigid adherence to the schedule if withdrawal symptoms emerge; prioritize patient tolerance over speed 3, 4

Psychological and Behavioral Support

• Cognitive behavioral therapy and interdisciplinary approaches can support patients during tapering 1
• Address possible anxiety related to the taper, underlying depression, and deficient pain and stress-coping strategies 1
• The addition of psychosocial care has been found to significantly reduce dropouts during medication tapers 1

Alternative Management if Taper Fails

• If you cannot tolerate the taper despite maximal supportive measures, consider maintaining at the lowest tolerable dose rather than forcing complete discontinuation 1
• Ensure alternative pain management strategies are optimized, including non-pharmacologic treatments and other medications appropriate for your underlying condition 3, 2